,text,position,name,last,events,dateString,collapsed,checked
0,"<p>New funding applications are referred to one of Pharmac's Funding Application Advisors (FAAs), who'll review the application to ensure they have the relevant information to undertake a preliminary analysis.&nbsp; They may seek more information if required.</p>
<p><a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/new-funding-applications/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/new-funding-applications/</a></p>",0,Application Received,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Aug 2003', 'fs': 'Aug 2003', 'change': None}, 'Event_Description': {'s': 'Application received', 'fs': 'Application received', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000B4iPB2AZ'}, 'Id': 'a0POZ00000B4iPB2AZ', 'Event_Date__c': '2003-08-01', 'Event_Description__c': 'Application received', 'Stage__c': 'Application Received', 'Formatted_Date__c': 'Aug 2003', 'Status_History__c': 'a132P000000AovoQAC'}, 'change': None}]",Aug 2003,False,True
1,"<p>Pharmac is identifying and gathering information required to get clinical advice.  The <a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/pharmacology-and-therapeutics-advisory-committee-ptac/"" rel=""nofollow"">Pharmacology and Therapeutics Advisory Committee (PTAC)</a>  meets quarterly. There are also around 20 expert <a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/specialist-advisory-committees/"" rel=""nofollow"">Specialist Advisory Committees (SACs)</a>, previously expert Subcommittees, which provide clinical evaluations in specialist areas. Specialist Advisory Committees meet as required to discuss issues referred to them by PTAC or Pharmac.</p>
<p style=""height: 20px"">&nbsp;</p>
<p>In November 2021, we introduced separate terms of reference for the SACs to make clear that these committees have different, but complementary, roles, expertise and perspectives to PTAC.</p>
<p style=""height: 15px"">&nbsp;</p>
<p>PTAC and SACs may make recommendations to Pharmac that differ from each other when looking at the same evidence. Pharmac considers the recommendations provided by all our clinical advisory committees when assessing applications.</p>
<p style=""height: 20px"">&nbsp;</p>
<p><a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/pharmacology-and-therapeutics-advisory-committee-ptac/ptac-terms-of-reference-july-2021/"" rel=""nofollow"">PTAC</a>  and <a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/specialist-advisory-committees/specialist-advisory-committee-terms-of-reference//"" rel=""nofollow"">Specialist Advisory Committees</a> records of the meeting will be published on this website in accordance with the Terms of Reference.</p>",1,Seeking Clinical Advice,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Aug 2003', 'fs': 'Aug 2003', 'change': None}, 'Event_Description': {'s': 'Clinical advice required', 'fs': 'Clinical advice required', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000B4iPC2AZ'}, 'Id': 'a0POZ00000B4iPC2AZ', 'Event_Date__c': '2003-08-01', 'Event_Description__c': 'Clinical advice required', 'Stage__c': 'Seeking Clinical Advice', 'Formatted_Date__c': 'Aug 2003', 'Status_History__c': 'a132P000000AovrQAC'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': 'These minutes have been ratified by the Pharmacology and Therapeutic Advisory Committee.', 'fs': 'These minutes have been ratified by the Pharmacology and Therapeutic Advisory Committee.', 'change': None}, 'Outcome': {'s': 'Decline', 'fs': 'Decline', 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Oct 2003', 'fs': 'Oct 2003', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Special Foods Subcommittee at meeting Wednesday 1 October 2003.', 'fs': 'Clinical advice received from Special Foods Subcommittee at meeting Wednesday 1 October 2003.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000B4iPD2AZ'}, 'Id': 'a0POZ00000B4iPD2AZ', 'Event_Date__c': '2003-10-01', 'Event_Description__c': 'Clinical advice received from Special Foods Subcommittee at meeting Wednesday 1 October 2003.', 'Stage__c': 'Seeking Clinical Advice', 'Outcome__c': 'Decline', 'Formatted_Date__c': 'Oct 2003', 'PTAC_Comments__c': 'These minutes have been ratified by the Pharmacology and Therapeutic Advisory Committee.', 'Status_History__c': 'a132P000000AowSQAS'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': 'Decline', 'fs': 'Decline', 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Feb 2004', 'fs': 'Feb 2004', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Sunday 1 February 2004.', 'fs': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Sunday 1 February 2004.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000B4iPE2AZ'}, 'Id': 'a0POZ00000B4iPE2AZ', 'Event_Date__c': '2004-02-01', 'Event_Description__c': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Sunday 1 February 2004.', 'Stage__c': 'Seeking Clinical Advice', 'Outcome__c': 'Decline', 'Formatted_Date__c': 'Feb 2004', 'Status_History__c': 'a132P000000AoxWQAS'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Sep 2006', 'fs': 'Sep 2006', 'change': None}, 'Event_Description': {'s': 'Clinical advice required', 'fs': 'Clinical advice required', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000B4iPI2AZ'}, 'Id': 'a0POZ00000B4iPI2AZ', 'Event_Date__c': '2006-09-01', 'Event_Description__c': 'Clinical advice required', 'Stage__c': 'Seeking Clinical Advice', 'Formatted_Date__c': 'Sep 2006', 'Status_History__c': 'a132P000000Ap89QAC'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': '<p>The Subcommittee recommended that the application for Prosure be declined at this time. The Subcommittee noted that if significant additional supporting data was available, or if the pricing could be improved, then the Subcommittee would welcome a reapplication.\xa0</p>', 'fs': '<p>The Subcommittee recommended that the application for Prosure be declined at this time. The Subcommittee noted that if significant additional supporting data was available, or if the pricing could be improved, then the Subcommittee would welcome a reapplication.\xa0</p>', 'change': None}, 'Published_Discussion': {'s': '<p>The Subcommittee noted that it was proposed that Prosure would be listed under a new heading for patients meeting the following Special Authority criteria\xa0</p><p><br></p><p>Initial applications from an Oncologist and valid for three months. Renewals from an Oncologist or General Practitioner on recommendation from an Oncologist and valid for three months.\xa0</p><p><br></p><p>Both:</p><p>Diagnosis of cancer with solid tumour; and</p><p>At risk of, or is, malnourished; and</p><p>To be used as a supplement.\xa0</p><p>Renewal where treatment remains appropriate and patient is continuing to benefit from treatment.</p><p><br></p><p>The Subcommittee considered that Prosure was not similar to any formulation currently listed on the Pharmaceutical Schedule.</p><p><br></p><p>The Subcommittee noted that it had considered an application to list Prosure on the Pharmaceutical Schedule in October 2003 when the Subcommittee declined the application.\xa0</p><p><br></p><p>The Subcommittee considered that Prosure did not present any significant additional clinical risk.\xa0</p><p><br></p><p>The Subcommittee considered that Prosure may be a beneficial supplement for cachexic patients with cancer, but noted that it was considerably more expensive than other supplements used in non-specific malnutrition.\xa0</p><p><br></p><p>The Subcommittee considered that the nutritional needs of patients with cancer may be sufficiently met by subsidised standard supplements with the addition of specific supplements which could be purchased over the counter.\xa0</p><p><br></p><p>The Subcommittee noted that listing Prosure on the Pharmaceutical Schedule may have a significant budgetary impact, as all patients with cancer would potentially be eligible for subsidy.</p><p>\xa0</p><p>The Subcommittee considered that the additional information provided was not sufficient to change its previous recommendation.\xa0</p><p><br></p>', 'fs': '<p>The Subcommittee noted that it was proposed that Prosure would be listed under a new heading for patients meeting the following Special Authority criteria\xa0</p><p><br></p><p>Initial applications from an Oncologist and valid for three months. Renewals from an Oncologist or General Practitioner on recommendation from an Oncologist and valid for three months.\xa0</p><p><br></p><p>Both:</p><p>Diagnosis of cancer with solid tumour; and</p><p>At risk of, or is, malnourished; and</p><p>To be used as a supplement.\xa0</p><p>Renewal where treatment remains appropriate and patient is continuing to benefit from treatment.</p><p><br></p><p>The Subcommittee considered that Prosure was not similar to any formulation currently listed on the Pharmaceutical Schedule.</p><p><br></p><p>The Subcommittee noted that it had considered an application to list Prosure on the Pharmaceutical Schedule in October 2003 when the Subcommittee declined the application.\xa0</p><p><br></p><p>The Subcommittee considered that Prosure did not present any significant additional clinical risk.\xa0</p><p><br></p><p>The Subcommittee considered that Prosure may be a beneficial supplement for cachexic patients with cancer, but noted that it was considerably more expensive than other supplements used in non-specific malnutrition.\xa0</p><p><br></p><p>The Subcommittee considered that the nutritional needs of patients with cancer may be sufficiently met by subsidised standard supplements with the addition of specific supplements which could be purchased over the counter.\xa0</p><p><br></p><p>The Subcommittee noted that listing Prosure on the Pharmaceutical Schedule may have a significant budgetary impact, as all patients with cancer would potentially be eligible for subsidy.</p><p>\xa0</p><p>The Subcommittee considered that the additional information provided was not sufficient to change its previous recommendation.\xa0</p><p><br></p>', 'change': None}, 'Published_Application': {'s': '<p>The Subcommittee considered an application from Abbott for Prosure, a 1.25 kcal/ml specialised oral feed for cachexic patients with cancer, presented in a 240 ml tetra pack in banana and vanilla flavours.</p>', 'fs': '<p>The Subcommittee considered an application from Abbott for Prosure, a 1.25 kcal/ml specialised oral feed for cachexic patients with cancer, presented in a 240 ml tetra pack in banana and vanilla flavours.</p>', 'change': None}, 'PTAC_Comments': {'s': 'These minutes have been ratified by the Pharmacology and Therapeutic Advisory Committee.', 'fs': 'These minutes have been ratified by the Pharmacology and Therapeutic Advisory Committee.', 'change': None}, 'Outcome': {'s': 'Decline', 'fs': 'Decline', 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Oct 2006', 'fs': 'Oct 2006', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Special Foods Subcommittee at meeting Wednesday 18 October 2006.', 'fs': 'Clinical advice received from Special Foods Subcommittee at meeting Wednesday 18 October 2006.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000B4iPJ2AZ'}, 'Id': 'a0POZ00000B4iPJ2AZ', 'Event_Date__c': '2006-10-18', 'Event_Description__c': 'Clinical advice received from Special Foods Subcommittee at meeting Wednesday 18 October 2006.', 'Stage__c': 'Seeking Clinical Advice', 'Outcome__c': 'Decline', 'Formatted_Date__c': 'Oct 2006', 'Published_Recommendation__c': '<p>The Subcommittee recommended that the application for Prosure be declined at this time. The Subcommittee noted that if significant additional supporting data was available, or if the pricing could be improved, then the Subcommittee would welcome a reapplication.\xa0</p>', 'Published_Application__c': '<p>The Subcommittee considered an application from Abbott for Prosure, a 1.25 kcal/ml specialised oral feed for cachexic patients with cancer, presented in a 240 ml tetra pack in banana and vanilla flavours.</p>', 'Published_Discussion__c': '<p>The Subcommittee noted that it was proposed that Prosure would be listed under a new heading for patients meeting the following Special Authority criteria\xa0</p><p><br></p><p>Initial applications from an Oncologist and valid for three months. Renewals from an Oncologist or General Practitioner on recommendation from an Oncologist and valid for three months.\xa0</p><p><br></p><p>Both:</p><p>Diagnosis of cancer with solid tumour; and</p><p>At risk of, or is, malnourished; and</p><p>To be used as a supplement.\xa0</p><p>Renewal where treatment remains appropriate and patient is continuing to benefit from treatment.</p><p><br></p><p>The Subcommittee considered that Prosure was not similar to any formulation currently listed on the Pharmaceutical Schedule.</p><p><br></p><p>The Subcommittee noted that it had considered an application to list Prosure on the Pharmaceutical Schedule in October 2003 when the Subcommittee declined the application.\xa0</p><p><br></p><p>The Subcommittee considered that Prosure did not present any significant additional clinical risk.\xa0</p><p><br></p><p>The Subcommittee considered that Prosure may be a beneficial supplement for cachexic patients with cancer, but noted that it was considerably more expensive than other supplements used in non-specific malnutrition.\xa0</p><p><br></p><p>The Subcommittee considered that the nutritional needs of patients with cancer may be sufficiently met by subsidised standard supplements with the addition of specific supplements which could be purchased over the counter.\xa0</p><p><br></p><p>The Subcommittee noted that listing Prosure on the Pharmaceutical Schedule may have a significant budgetary impact, as all patients with cancer would potentially be eligible for subsidy.</p><p>\xa0</p><p>The Subcommittee considered that the additional information provided was not sufficient to change its previous recommendation.\xa0</p><p><br></p>', 'PTAC_Comments__c': 'These minutes have been ratified by the Pharmacology and Therapeutic Advisory Committee.', 'Status_History__c': 'a132P000000Ap8vQAC'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': 'Decline', 'fs': 'Decline', 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'May 2007', 'fs': 'May 2007', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 10 May 2007.', 'fs': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 10 May 2007.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000B4iPK2AZ'}, 'Id': 'a0POZ00000B4iPK2AZ', 'Event_Date__c': '2007-05-10', 'Event_Description__c': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 10 May 2007.', 'Stage__c': 'Seeking Clinical Advice', 'Outcome__c': 'Decline', 'Formatted_Date__c': 'May 2007', 'Status_History__c': 'a132P000000ApCBQA0'}, 'change': None}]",Aug 2003,False,True
2,"<p>Following Clinical Advice, Pharmac staff considers the advice and the funding application under goes an assessment using our&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/factors-for-consideration/"" rel=""nofollow"">Factors for Consideration</a>&nbsp;framework and seeks additional information as required.</p>
<p>&nbsp;</p>
<p>Research and Economic analysis are undertaken.&nbsp; This focuses on the costs and benefits of a proposed course of action. Economics is based on three fundamental concepts that summarise the issues Pharmac faces daily:&nbsp;</p>
<ul>
<li>Scarcity &ndash; resources will always be insufficient to support all possible activities.</li>
<li>Choices &ndash; due to scarce resources, decisions must be made about how best to use them.</li>
<li>Opportunity cost &ndash; by choosing to use resources one way, we forgo other opportunities to use the same resources.</li>
</ul>
<p>&nbsp;</p>
<p>For further information on the purpose of, and techniques for, undertaking economic analysis in health care, please refer&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/economic-analysis/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/economic-analysis/</a></p>",2,Under Assessment,False,,,False,False
3,"<p>Pharmac staff uses a prioritisation process to compare and rank funding options. Possible opportunities for new investment will always exceed the budget Pharmac has available; therefore, prioritisation is an intrinsic part of Pharmacâ€™s decision-making process.</p>
<p>The relative ranking of options aims to support Pharmac&rsquo;s statutory objective &ldquo;to secure for eligible people in need of pharmaceuticals, the best health outcomes that are reasonably achievable from pharmaceutical treatment and from within the amount of funding provided&rdquo;.</p>
<p>A funding application or proposal is considered ready for prioritisation when sufficient information is available to permit it to be reviewed against Pharmac's Factors for Consideration and to inform a comparison with other possible investment decisions.</p>
<p>There is no guarantee when or if a ranked medicine will be funded.&nbsp;&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/prioritisation/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/prioritisation/</a></p>",3,Options Compared,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Feb 2004', 'fs': 'Feb 2004', 'change': None}, 'Event_Description': {'s': 'The relative ranking of the pharmaceutical application has been completed.', 'fs': 'The relative ranking of the pharmaceutical application has been completed.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000B4iPF2AZ'}, 'Id': 'a0POZ00000B4iPF2AZ', 'Event_Date__c': '2004-02-01', 'Event_Description__c': 'The relative ranking of the pharmaceutical application has been completed.', 'Stage__c': 'Options Compared', 'Formatted_Date__c': 'Feb 2004', 'Status_History__c': 'a132P000000AoxXQAS'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Nov 2013', 'fs': 'Nov 2013', 'change': None}, 'Event_Description': {'s': 'The relative ranking of the pharmaceutical application has been completed.', 'fs': 'The relative ranking of the pharmaceutical application has been completed.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000B4iPL2AZ'}, 'Id': 'a0POZ00000B4iPL2AZ', 'Event_Date__c': '2013-11-05', 'Event_Description__c': 'The relative ranking of the pharmaceutical application has been completed.', 'Stage__c': 'Options Compared', 'Formatted_Date__c': 'Nov 2013', 'Status_History__c': 'a132P000000AqVjQAK'}, 'change': None}]",Feb 2004,False,True
4,"<p>Pharmac is consulting on a proposal to either approve or decline the application.&nbsp;We seek the views of all people who have an interest in our proposals, or who may be affected by them, to obtain feedback on our proposed approaches.</p>
<p><a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/having-your-say/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/having-your-say/</a></p>",4,Under Consultation,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': '<p><a href=""https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/2023-12-proposal-to-decline-inactive-funding-applications-2"" target=""_blank"">Consultation notification</a></p>', 'fs': '<p><a href=""https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/2023-12-proposal-to-decline-inactive-funding-applications-2"" target=""_blank"">Consultation notification</a></p>', 'change': None}, 'Formatted_Date': {'s': 'Dec 2023', 'fs': 'Dec 2023', 'change': None}, 'Event_Description': {'s': 'Public consultation for this application is active.', 'fs': 'Public consultation for this application is active.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000B4iPM2AZ'}, 'Id': 'a0POZ00000B4iPM2AZ', 'Event_Date__c': '2023-12-18', 'Event_Description__c': 'Public consultation for this application is active.', 'Stage__c': 'Under Consultation', 'Links__c': '<p><a href=""https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/2023-12-proposal-to-decline-inactive-funding-applications-2"" target=""_blank"">Consultation notification</a></p>', 'Formatted_Date__c': 'Dec 2023', 'Status_History__c': 'a13OZ000004klCvYAI'}, 'change': None}]",Dec 2023,False,True
5,"<p>Following the consultation process, Pharmac staff considers the feedback and identifies any additional information required as part of a gap analysis.&nbsp; The proposal may require further clinical advice, research, and assessment.</p>",5,Reviewing Consultation Feedback,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Feb 2024', 'fs': 'Feb 2024', 'change': None}, 'Event_Description': {'s': 'Public consultation for this application is now closed. Pharmac is reviewing consultation feedback.', 'fs': 'Public consultation for this application is now closed. Pharmac is reviewing consultation feedback.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000B4iPN2AZ'}, 'Id': 'a0POZ00000B4iPN2AZ', 'Event_Date__c': '2024-02-12', 'Event_Description__c': 'Public consultation for this application is now closed. Pharmac is reviewing consultation feedback.', 'Stage__c': 'Reviewing Consultation Feedback', 'Formatted_Date__c': 'Feb 2024', 'Status_History__c': 'a13OZ000006lujKYAQ'}, 'change': None}]",Feb 2024,False,True
6,"<p>We refer to our decisions about whether and how particular pharmaceuticals are publicly-funded, as &ldquo;funding decisions&rdquo;.</p>
<p>We consider and assess all funding decisions using the&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/about/operating-policies-and-procedures/#factorsfc"" rel=""nofollow"">Factors for Consideration</a>. When we do so, we carefully evaluate clinical and other evidence for the benefits and suitability of a proposal, and to identify and understand the people who will be affected by it.</p>
<p>While our main task is to allocate pharmaceutical funding, we consider the benefits and costs across the whole health system now and with a long-term focus, including the effects for hospitals and primary care, and consider direct costs to patients as well as to all health sector budgets.</p>
<p>Final funding decisions are made by the Pharmac Board or delegated to senior Pharmac staff as required by the Board.</p>
<p>&nbsp;</p>",6,Decision,True,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'May 2004', 'fs': 'May 2004', 'change': None}, 'Event_Description': {'s': 'The funding application has been declined.', 'fs': 'The funding application has been declined.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000B4iPG2AZ'}, 'Id': 'a0POZ00000B4iPG2AZ', 'Event_Date__c': '2004-05-01', 'Event_Description__c': 'The funding application has been declined.', 'Stage__c': 'Decision', 'Formatted_Date__c': 'May 2004', 'Status_History__c': 'a132P000000AozCQAS'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Sep 2006', 'fs': 'Sep 2006', 'change': None}, 'Event_Description': {'s': 'Received Additional Information', 'fs': 'Received Additional Information', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000B4iPH2AZ'}, 'Id': 'a0POZ00000B4iPH2AZ', 'Event_Date__c': '2006-09-01', 'Event_Description__c': 'Received Additional Information', 'Stage__c': 'Decision', 'Formatted_Date__c': 'Sep 2006', 'Status_History__c': 'a132P000000Ap85QAC'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': '<p><a href=""https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/decision-to-decline-inactive-funding-applications-july-24"" target=""_blank"">Decision notification</a></p>', 'fs': '<p><a href=""https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/decision-to-decline-inactive-funding-applications-july-24"" target=""_blank"">Decision notification</a></p>', 'change': None}, 'Formatted_Date': {'s': 'Jul 2024', 'fs': 'Jul 2024', 'change': None}, 'Event_Description': {'s': 'The funding application has been declined.', 'fs': 'The funding application has been declined.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000B4iPO2AZ'}, 'Id': 'a0POZ00000B4iPO2AZ', 'Event_Date__c': '2024-07-29', 'Event_Description__c': 'The funding application has been declined.', 'Stage__c': 'Decision', 'Links__c': '<p><a href=""https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/decision-to-decline-inactive-funding-applications-july-24"" target=""_blank"">Decision notification</a></p>', 'Formatted_Date__c': 'Jul 2024', 'Status_History__c': 'a13OZ00000Cg8jqYAB'}, 'change': None}]",May 2004,False,True
